Trials / Completed
CompletedNCT03088137
Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment
Multicentre Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- IVFarma LLC · Industry
- Sex
- Female
- Age
- 20 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to show equivalence with regard to the number of oocytes retrieved between follitropin alfa (pen-injectors) Primapur® and Gonal-f® in woman undergoing IVF/ICSI
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Follitropin alfa (Gonal-f) | Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation |
| DRUG | Follitropin alfa (Primapur) | Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation |
Timeline
- Start date
- 2017-02-08
- Primary completion
- 2018-08-17
- Completion
- 2018-08-17
- First posted
- 2017-03-23
- Last updated
- 2022-04-01
- Results posted
- 2019-06-06
Locations
3 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT03088137. Inclusion in this directory is not an endorsement.